Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garcon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonniere B, Strubi-Vuillaume I, Zahr N, Destee A, Corvol JC, Poltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, & Bordet R Antioxid. Redox Signal., 21:195-210, 2014. Paper doi bibtex @article{devos_d_targeting_2014,
title = {Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease},
volume = {21},
issn = {1523-0864},
url = {http://www.ncbi.nlm.nih.gov/pubmed/24251381},
DOI = {10.1089/ars.2013.5593},
Language = {English},
Journal = {Antioxid. Redox Signal.},
author = {{Devos D} and {Moreau C} and {Devedjian JC} and {Kluza J} and {Petrault M} and {Laloux C} and {Jonneaux A} and {Ryckewaert G} and {Garcon G} and {Rouaix N} and {Duhamel A} and {Jissendi P} and {Dujardin K} and {Auger F} and {Ravasi L} and {Hopes L} and {Grolez G} and {Firdaus W} and {Sablonniere B} and {Strubi-Vuillaume I} and {Zahr N} and {Destee A} and {Corvol JC} and {Poltl D} and {Leist M} and {Rose C} and {Defebvre L} and {Marchetti P} and {Cabantchik ZI} and {Bordet R}},
year = {2014},
keywords = {Animals, Cell Line, Combined Modality Therapy, Disease Models, Animal, Double-Blind Method, Humans, Iron/metabolism*, Iron Chelating Agents/administration & dosage, Iron Chelating Agents/therapeutic use*, Male, Mice, Mice, Inbred C57BL, Motor Activity/drug effects, Oxidative Stress/drug effects, Parkinson Disease/drug therapy*, Parkinson Disease/metabolism*, Pilot Projects, Pyridones/administration & dosage, Pyridones/pharmacology, Pyridones/therapeutic use*},
pages = {195-210}
}
Downloads: 0
{"_id":"dS2NMwDLeYYfiQiEd","bibbaseid":"devosd-moreauc-devedjianjc-kluzaj-petraultm-lalouxc-jonneauxa-ryckewaertg-etal-targetingchelatableironasatherapeuticmodalityinparkinsonsdisease-2014","authorIDs":[],"author_short":["Devos D","Moreau C","Devedjian JC","Kluza J","Petrault M","Laloux C","Jonneaux A","Ryckewaert G","Garcon G","Rouaix N","Duhamel A","Jissendi P","Dujardin K","Auger F","Ravasi L","Hopes L","Grolez G","Firdaus W","Sablonniere B","Strubi-Vuillaume I","Zahr N","Destee A","Corvol JC","Poltl D","Leist M","Rose C","Defebvre L","Marchetti P","Cabantchik ZI","Bordet R"],"bibdata":{"bibtype":"article","type":"article","title":"Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease","volume":"21","issn":"1523-0864","url":"http://www.ncbi.nlm.nih.gov/pubmed/24251381","doi":"10.1089/ars.2013.5593","language":"English","journal":"Antioxid. Redox Signal.","author":[{"firstnames":[],"propositions":[],"lastnames":["Devos D"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Moreau C"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Devedjian JC"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Kluza J"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Petrault M"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Laloux C"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Jonneaux A"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Ryckewaert G"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Garcon G"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Rouaix N"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Duhamel A"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Jissendi P"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Dujardin K"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Auger F"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Ravasi L"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Hopes L"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Grolez G"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Firdaus W"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Sablonniere B"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Strubi-Vuillaume I"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Zahr N"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Destee A"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Corvol JC"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Poltl D"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Leist M"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Rose C"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Defebvre L"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Marchetti P"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Cabantchik ZI"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Bordet R"],"suffixes":[]}],"year":"2014","keywords":"Animals, Cell Line, Combined Modality Therapy, Disease Models, Animal, Double-Blind Method, Humans, Iron/metabolism*, Iron Chelating Agents/administration & dosage, Iron Chelating Agents/therapeutic use*, Male, Mice, Mice, Inbred C57BL, Motor Activity/drug effects, Oxidative Stress/drug effects, Parkinson Disease/drug therapy*, Parkinson Disease/metabolism*, Pilot Projects, Pyridones/administration & dosage, Pyridones/pharmacology, Pyridones/therapeutic use*","pages":"195-210","bibtex":"@article{devos_d_targeting_2014,\r\ntitle = {Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease},\r\nvolume = {21},\r\nissn = {1523-0864},\r\nurl = {http://www.ncbi.nlm.nih.gov/pubmed/24251381},\r\nDOI = {10.1089/ars.2013.5593},\r\nLanguage = {English},\r\nJournal = {Antioxid. Redox Signal.},\r\nauthor = {{Devos D} and {Moreau C} and {Devedjian JC} and {Kluza J} and {Petrault M} and {Laloux C} and {Jonneaux A} and {Ryckewaert G} and {Garcon G} and {Rouaix N} and {Duhamel A} and {Jissendi P} and {Dujardin K} and {Auger F} and {Ravasi L} and {Hopes L} and {Grolez G} and {Firdaus W} and {Sablonniere B} and {Strubi-Vuillaume I} and {Zahr N} and {Destee A} and {Corvol JC} and {Poltl D} and {Leist M} and {Rose C} and {Defebvre L} and {Marchetti P} and {Cabantchik ZI} and {Bordet R}},\r\nyear = {2014},\r\nkeywords = {Animals, Cell Line, Combined Modality Therapy, Disease Models, Animal, Double-Blind Method, Humans, Iron/metabolism*, Iron Chelating Agents/administration & dosage, Iron Chelating Agents/therapeutic use*, Male, Mice, Mice, Inbred C57BL, Motor Activity/drug effects, Oxidative Stress/drug effects, Parkinson Disease/drug therapy*, Parkinson Disease/metabolism*, Pilot Projects, Pyridones/administration & dosage, Pyridones/pharmacology, Pyridones/therapeutic use*},\r\npages = {195-210}\r\n}\r\n\r\n","author_short":["Devos D","Moreau C","Devedjian JC","Kluza J","Petrault M","Laloux C","Jonneaux A","Ryckewaert G","Garcon G","Rouaix N","Duhamel A","Jissendi P","Dujardin K","Auger F","Ravasi L","Hopes L","Grolez G","Firdaus W","Sablonniere B","Strubi-Vuillaume I","Zahr N","Destee A","Corvol JC","Poltl D","Leist M","Rose C","Defebvre L","Marchetti P","Cabantchik ZI","Bordet R"],"key":"devos_d_targeting_2014","id":"devos_d_targeting_2014","bibbaseid":"devosd-moreauc-devedjianjc-kluzaj-petraultm-lalouxc-jonneauxa-ryckewaertg-etal-targetingchelatableironasatherapeuticmodalityinparkinsonsdisease-2014","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/24251381"},"keyword":["Animals","Cell Line","Combined Modality Therapy","Disease Models","Animal","Double-Blind Method","Humans","Iron/metabolism*","Iron Chelating Agents/administration & dosage","Iron Chelating Agents/therapeutic use*","Male","Mice","Mice","Inbred C57BL","Motor Activity/drug effects","Oxidative Stress/drug effects","Parkinson Disease/drug therapy*","Parkinson Disease/metabolism*","Pilot Projects","Pyridones/administration & dosage","Pyridones/pharmacology","Pyridones/therapeutic use*"],"downloads":0},"bibtype":"article","biburl":"https://pro.univ-lille.fr/fileadmin/user_upload/pages_pros/patrick_devos/duhamel.bib","creationDate":"2019-06-21T09:30:55.056Z","downloads":0,"keywords":["animals","cell line","combined modality therapy","disease models","animal","double-blind method","humans","iron/metabolism*","iron chelating agents/administration & dosage","iron chelating agents/therapeutic use*","male","mice","mice","inbred c57bl","motor activity/drug effects","oxidative stress/drug effects","parkinson disease/drug therapy*","parkinson disease/metabolism*","pilot projects","pyridones/administration & dosage","pyridones/pharmacology","pyridones/therapeutic use*"],"search_terms":["targeting","chelatable","iron","therapeutic","modality","parkinson","disease","devos d","moreau c","devedjian jc","kluza j","petrault m","laloux c","jonneaux a","ryckewaert g","garcon g","rouaix n","duhamel a","jissendi p","dujardin k","auger f","ravasi l","hopes l","grolez g","firdaus w","sablonniere b","strubi-vuillaume i","zahr n","destee a","corvol jc","poltl d","leist m","rose c","defebvre l","marchetti p","cabantchik zi","bordet r"],"title":"Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease","year":2014,"dataSources":["Tt6zYqvN5kE3wbwiR"]}